Facebook – a drug advertisers might be ready to go cold turkey on?
Although the social network’s advertising revenue has reached $11bn this quarter, Zuckerberg should not get too comfortable yet as the real fallout from Cambridge Analytica remains on the horizon, argues Eleanor Dickinson.
The executives at Facebook must be feeling rather self-satisfied this week.
Despite recently experiencing perhaps the worst month in the company’s history when the Cambridge Analytica scandal exploded across the world and the firm became public enemy number one, the platform’s earnings released yesterday painted a very positive picture.
The social network’s revenue has climbed by 49 percent to reach US$11.966 billion in the last quarter. Its advertising revenue has been strong too, rising by 50 percent to US$11.795bn from the same quarter last year. Additionally, its daily active user numbers have remained at a consistent 1.45 billion, despite the high-profile #DeleteFacebook campaign.
